Utilizing Autologous Multipotent Mesenchymal Stromal Cells and -Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial.
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378041%3A_____%2F16%3A00459625" target="_blank" >RIV/68378041:_____/16:00459625 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1155/2016/2076061" target="_blank" >http://dx.doi.org/10.1155/2016/2076061</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1155/2016/2076061" target="_blank" >10.1155/2016/2076061</a>
Alternative languages
Result language
angličtina
Original language name
Utilizing Autologous Multipotent Mesenchymal Stromal Cells and -Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial.
Original language description
The purpose of this prospective controlled study was to compare healing quality following the implantation of ultraporous β-tricalcium phosphate, containing either expanded autologous mesenchymal stromal cells (trial group, 9 patients) or β-tricalcium phosphate alone (control group, 9 patients), into femoral defects during revision total hip arthroplasty. Both groups were assessed using the Harris Hip Score, radiography, and DEXA scanning at 6 weeks and 3, 6, and 12 months postoperatively. A significant difference in the bone defect healing was observed between both groups of patients (P<0.05). In the trial group, trabecular remodeling was found in all nine patients and in the control group, in 1 patient only. Whereas, over the 12-month follow-up period, no significant difference was observed between both groups of patients in terms of the resorption of β-tricalcium phosphate, the significant differences were documented in the presence of radiolucency and bone trabeculation through the defect (P<0.05). Using autologous mesenchymal stromal cells combined with a β-tricalcium phosphate scaffold is a feasible, safe, and effective approach for management of bone defects with compromised microenvironment. The clinical trial was registered at the EU Clinical Trials Register before patient recruitment has begun (EudraCT number 2012-005599-33).
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FI - Traumatology and orthopaedics
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
BioMed Research International
ISSN
2314-6141
e-ISSN
—
Volume of the periodical
2016
Issue of the periodical within the volume
2016
Country of publishing house
US - UNITED STATES
Number of pages
13
Pages from-to
—
UT code for WoS article
000374390000001
EID of the result in the Scopus database
2-s2.0-84965149669